ClinicalTrials.gg
Active, not recruitingNCT06548217Updated Oct 8, 2026

A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of ONO-4538HSC in Advanced or Metastatic Solid Tumors, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 8 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, uncontrolled, phase I study to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ONO-4538HSC administered subcutaneously in participants with advanced or metastatic solid tumors. This study consists of the tolerability confirmation part to determine the recommended dose for Japanese participants by evaluating the DLTs and the expansion part to evaluate the safety and pharmacokinetics and to explore the efficacy.

02

Conditions studied

  • Advanced or Metastatic Solid Tumors
03

In context

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with advanced or solid tumors
  2. Patients have an performance status of 0 to 1
  3. Patients with a of at least 3 months

    [Tolerability confirmation part]

  4. Patients who are or intolerant to standard therapy or for whom no standard therapy is available

    [Expansion part]

  5. Patients who are refractory or intolerant to standard therapy, or for whom no standard therapy is available, or for whom monotherapy with intravenous nivolumab is indicated according to the package insert

Exclusion criteria

Exclusion Criteria:

  1. Patients with a complication or history of severe to any antibody product
  2. Patients with severe complication
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    ONO-4538HSC

    Drug: ONO-4538HSC

Interventions

  • DrugONO-4538HSC

    ONO-4538HSC will be administered subcutaneously once every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities (DLT)

    Time frame: 28 days

  2. Adverse event (AE)

    Time frame: UP to 100 days after the last dose

Secondary outcomes

  1. Pharmacokinetics(serum concentration of Nivolumab)

    Time frame: Up to Cycle25 (each cycle is 28 days) and Post-treatment observation phase (28 days after the end of treatment phase)

Other outcomes

  1. Overall response rate (ORR)

    Time frame: Through study completion, an average of 6 months

  2. Disease control rate (DCR)

    Time frame: Through study completion, an average of 6 months

  3. Overall survival (OS)

    Time frame: Through study completion, an average of 6 months

  4. Progression-free survival (PFS)

    Time frame: Through study completion, an average of 6 months

  5. Duration of response (DOR)

    Time frame: Through study completion, an average of 6 months

  6. Time to response (TTR)

    Time frame: Through study completion, an average of 6 months

  7. Best overall response (BOR)

    Time frame: Through study completion, an average of 6 months

  8. Percentage of change in the sum of tumor diameters of target lesions

    Time frame: Through study completion, an average of 6 months

  9. Maximum percent change in the sum diameters of the target lesions

    Time frame: Through study completion, an average of 6 months

  10. Anti-Nivolumab antibody

    Time frame: Up to Cycle25 (each cycle is 28 days) and Post-treatment observation phase (28 days after the end of treatment phase)

  11. Anti-rHuPH20 antibody

    Time frame: Up to Cycle25 (each cycle is 28 days) and Post-treatment observation phase (28 days after the end of treatment phase)

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Feb 2028, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 12, 2024
StartActual
May 7, 2024
Primary completionEst.
Feb 29, 2028
CompletionEst.
Feb 29, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06548217
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
May 7, 2024
Primary completion
Feb 29, 2028 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion